Tislelizumab

File:Tislelizumab PB-1 7BXA.png

Tislelizumab PB-1 7BXA

Tislelizumab is a monoclonal antibody used in the treatment of various types of cancer. It is specifically designed to target and inhibit the programmed cell death protein 1 (PD-1) pathway, which is a mechanism that tumors use to evade the immune system.

Mechanism of Action

Tislelizumab works by binding to the PD-1 receptor on T cells, a type of white blood cell that plays a crucial role in the body's immune response. By inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2, tislelizumab enhances the immune system's ability to detect and destroy cancer cells.

Indications

Tislelizumab is approved for the treatment of several types of cancer, including:

• Non-small cell lung cancer (NSCLC)
• Hodgkin lymphoma
• Urothelial carcinoma

Clinical Trials

Tislelizumab has undergone extensive clinical trials to evaluate its efficacy and safety. These trials have demonstrated significant anti-tumor activity and manageable safety profiles in patients with various types of cancer.

Side Effects

Common side effects of tislelizumab include:

• Fatigue
• Nausea
• Diarrhea
• Rash
• Pruritus

Serious side effects may include immune-related adverse events such as pneumonitis, hepatitis, colitis, and endocrinopathies.

Development and Approval

Tislelizumab was developed by BeiGene, a global biotechnology company. It has received approval from regulatory agencies in several countries for the treatment of specific types of cancer.

See Also

• Monoclonal antibody therapy
• Cancer immunotherapy
• Programmed cell death protein 1